Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.
2.
3.

Racial differences in prediction of time to prostate cancer diagnosis in a prospective screening cohort of high-risk men: effect of TMPRSS2 Met160Val.

Giri VN, Ruth K, Hughes L, Uzzo RG, Chen DY, Boorjian SA, Viterbo R, Rebbeck TR.

BJU Int. 2011 Feb;107(3):466-70. doi: 10.1111/j.1464-410X.2010.09522.x.

4.

Latent class cluster analysis to understand heterogeneity in prostate cancer treatment utilities.

Meghani SH, Lee CS, Hanlon AL, Bruner DW.

BMC Med Inform Decis Mak. 2009 Nov 27;9:47. doi: 10.1186/1472-6947-9-47.

5.

Prostate cancer early detection program recruitment methods and show rates in men at high risk.

Giri VN, Coups EJ, Ruth K, Goplerud J, Raysor S, Kim TY, Bagden L, Mastalski K, Zakrzewski D, Leimkuhler S, Watkins-Bruner D.

J Urol. 2009 Nov;182(5):2212-7. doi: 10.1016/j.juro.2009.07.021.

6.

Dairy intake and 1,25-dihydroxyvitamin D levels in men at high risk for prostate cancer.

Tseng M, Giri V, Watkins-Bruner D, Giovannucci E.

Cancer Causes Control. 2009 Dec;20(10):1947-54. doi: 10.1007/s10552-009-9389-9.

7.

Prevalence and correlates of vitamin D status in African American men.

Tseng M, Giri V, Bruner DW, Giovannucci E.

BMC Public Health. 2009 Jun 18;9:191. doi: 10.1186/1471-2458-9-191.

8.

Race, genetic West African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men.

Giri VN, Egleston B, Ruth K, Uzzo RG, Chen DY, Buyyounouski M, Raysor S, Hooker S, Torres JB, Ramike T, Mastalski K, Kim TY, Kittles R.

Cancer Prev Res (Phila). 2009 Mar;2(3):244-50. doi: 10.1158/1940-6207.CAPR-08-0150.

9.
Items per page

Supplemental Content

Support Center